Skip to content
You are now leaving https://www.ionispharma.com to visit

The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy

SPINRAZA demonstrated stabilization or improvement in motor function in individuals with spinal muscular atrophy (SMA) where the natural history of the disease is a decline in motor function over time The majority of individuals treated with SPINRAZA demonstrated benefits in upper limb and general